Cited by 74Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study

Open access

Citrome, Leslie, Ota, Ai, Nagamizu, Kazuhiro, Perry, Pamela, Weiller, Emmanuelle, Baker, Ross A.·2016·International Clinical Psychopharmacology

DOI 10.1097/yic.0000000000000123

Open this paper in CoChat — free account

Abstract

The aim of this study was to explore the effects of brexpiprazole and aripiprazole on efficacy, cognitive functioning, and safety in patients with acute schizophrenia. Patients who would benefit from hospitalization/continued hospitalization for acute relapse of schizophrenia were enrolled and randomized (2 : 1) to target doses of open-label brexpiprazole 3 mg/day or aripiprazole 15 mg/day for 6 weeks. Outcomes included change from baseline to week 6 in the Positive and Negative Syndrome Scale total score, Barratt Impulsiveness Scale 11-item score, and Cogstate computerized cognitive test battery scores. Patients treated with brexpiprazole (n=64) or aripiprazole (n=33) showed reductions in symptoms of schizophrenia as assessed by Positive and Negative Syndrome Scale total score (-22.9 and -19.4, respectively). A modest reduction in impulsivity was observed with brexpiprazole, but not aripiprazole (mean change in the Barratt Impulsiveness Scale 11-item total score: -2.7 and 0.1, respectively). No change in Cogstate scores was observed for either treatment. Brexpiprazole was well tolerated and the incidence of akathisia was lower in patients treated with brexpiprazole (9.4%) than aripiprazole (21.2%). Clinically relevant improvements in psychopathology were observed in patients with acute schizophrenia treated with brexpiprazole or aripiprazole. Brexpiprazole was well tolerated, with a lower incidence of akathisia than aripiprazole.

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000123

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 3×
“Safety and tolerability assessments included AEs; the following EPS scales: Simpson Angus Scale (Simpson and Angus, 1970), Abnormal Involuntary Movement Scale (Guy, 1976), and the Barnes Akathisia Rating Scale (BARS) (Barnes, 1989); body weight; laboratory tests; vital signs; Columbia Suicide Severity Rating Scale (Po…”
Method
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 4×
“…the variability in accompanying side effects (Correll, 2010), including weight gain, sedation, restlessness/agitation, akathisia, QTc prolongation, extrapyramidal symptoms (EPSs), and hyperprolactinemia (and associated sexual effects) (Kane et al., 2010; De Hert et al., 2012b; Leucht et al., 2013).”
BackgroundInfluential
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
A Systematic Review of the Prevalence of Schizophrenia
Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S. M., Arrington, E. G., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. B. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 982

Show all 41 references

Research works printed but not linked: 3

Celada, 2004, J Psychiatry Neurosci, 29, 252
Levi, 2013, Curr Psychiatry, 12, 38
Sheehan, 1998, J Clin Psychiatry, 59, 22

Sorted by citations

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Polypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 245
Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
“Brexpiprazole vs aripiprazole At this time, there has been one open-label trial comparing brexpiprazole 3 mg daily to aripiprazole 15 mg daily for the acute (6-week) treatment of schizophrenia.(18) Participants were enrolled in this study if they were having an acute relapse of schizophrenia, and were then randomized…”
Self-citation
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Lobo, M. C., Whitehurst, T., Kaar, S. J., & Howes, O. D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.032 · Cited by 97
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 74
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12180 · Cited by 63
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Self-citation
Brexpiprazole: A Review in Schizophrenia
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-1052-5 · Cited by 57
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Self-citation
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Mohr, P., Masopust, J., & Kopeček, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.781946 · Cited by 61
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
Forbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52
Up-to-date expert opinion on the safety of recently developed antipsychotics
Orsolini, L., Berardis, D. D., & Volpe, U. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1795126 · Cited by 52
New Antipsychotic Medications in the Last Decade
Pahwa, M., Sleem, A., Elsayed, O. H., Good, M. E., & El‐Mallakh, R. S. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01298-w · Cited by 50
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis
Demyttenaere, K., Detraux, J., Racagni, G., & Vansteelandt, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00625-3 · Cited by 53
Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
Siwek, M., Wojtasik-Bakalarz, K., Krupa, A. J., & Chrobak, A. A. (2023) · Brain Sciences · doi:10.3390/brainsci13030397 · Cited by 41
Brexpiprazole: First Global Approval
Greig, S. L. (2015) · Drugs · doi:10.1007/s40265-015-0462-2 · Cited by 41
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 40
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
Suzuki, S., Yamamoto, M., Sanomachi, T., Togashi, K., Sugai, A., Seino, S., Yoshioka, T., Kitanaka, C., & Okada, M. (2019) · Cancers · doi:10.3390/cancers11070947 · Cited by 36
Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
Marder, S. R., Hakala, M., Josiassen, M. K., Zhang, P. G. Y., Ouyang, J., Weiller, E., Weiss, C., & Hobart, M. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.57 · Cited by 35
Self-citation
Brexpiprazole: A Review in Schizophrenia
Garnock-Jones, K. P. (2016) · CNS Drugs · doi:10.1007/s40263-016-0325-8 · Cited by 30
Clinical role of brexpiprazole in depression and schizophrenia
Parikh, N., Robinson, D. A., & Clayton, A. H. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s94060 · Cited by 30
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
Watanabe, Y., Yamada, S., Otsubo, T., & Kikuchi, T. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s240859 · Cited by 29
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay, R. P., Citrome, L., Samalin, L., Liu, C., Thomsen, M. S., Correll, C. U., Hameg, A., & Llorca, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1149164 · Cited by 30
Self-citation
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., & Iwata, N. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05472-5 · Cited by 27
Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., & Iwata, N. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.04.032 · Cited by 27
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
Crespo‐Facorro, B., Pelayo‐Terán, J. M., & Son, J. M.-V. (2016) · Neurology and Therapy · doi:10.1007/s40120-016-0050-8 · Cited by 27
Brexpiprazole: a new leaf on the partial dopamine agonist branch
Hope, J., Castle, D. J., & Keks, N. A. (2017) · Australasian Psychiatry · doi:10.1177/1039856217732473 · Cited by 24
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder
McKeage, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0320-0 · Cited by 23
Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment
Musco, S. E., McAllister, V., & Caudle, I. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937575 · Cited by 21
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials
Antoun, A., Girgis, E., & Mishriky, R. S. L. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000308 · Cited by 20
Involvement of presynaptic 5-HT 1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats
Mombereau, C., Arnt, J., & Mørk, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.015 · Cited by 19
Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents
Kannarkat, G. T., Caroff, S. N., & Morley, J. F. (2022) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.695 · Cited by 20
The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework
Martins, R., Kadakia, A., Williams, G. R., Milanovic, S. M., & Connolly, M. P. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14746 · Cited by 15
Brexpiprazole in the Treatment of Schizophrenia and Agitation in Alzheimer’s Disease
Stummer, L., Marković, M., & Maroney, M. E. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0013 · Cited by 16
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study
van Erp, T. G., Baker, R. A., Cox, K., Okame, T., Kojima, Y., Eramo, A., & Potkin, S. G. (2020) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2020.111085 · Cited by 14
Self-citation
Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
McDonagh, M. S., Dana, T., Selph, S., Devine, E. B., Cantor, A. G., Bougatsos, C., Blazina, I., Grusing, S., Fu, R. F., & Haupt, D. W. (2020) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20200004 · Cited by 13
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice
Edinoff, A. N., Wu, N. W., Maxey, B. S., Ren, A. L., Leethy, K. N., Girma, B., Odisho, A. S., Kaye, J. S., Kaye, A. J., Kaye, A. M., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4399 · Cited by 12
Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis
Ng‐Mak, D., Tongbram, V., Ndirangu, K., Rajagopalan, K., & Loebel, A. D. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0016 · Cited by 12
Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study
Lombardozzi, G., Trovini, G., Amici, E., Kotzalidis, G. D., Perrini, F., Giovanetti, V., Giovanni, A. D., & Filippis, S. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1321233 · Cited by 12
Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects
Sanagawa, A., Shiraishi, N., Sekiguchi, F., Akechi, T., & Kimura, K. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001127 · Cited by 12
Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications
IsHak, W. W., Hirsch, D., Renteria, S., Totlani, J., Murphy, N., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Keerthana, S., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07141-3 · Cited by 10
Augmentation Therapy With Serotonin 5‐ HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies
Yamada, R., Wada, A., Stickley, A., Newman‐Tancredi, A., & Sumiyoshi, T. (2025) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70023 · Cited by 7
Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia
Kowalczyk, E., Koziej, S., & Soroka, E. (2024) · Medical Science Monitor · doi:10.12659/msm.945412 · Cited by 12
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy
Yan, T., Greene, M., Chang, E. Y., Houle, C. R., Waters, H. C., Tarbox, M. H., & Broder, M. S. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.11.009 · Cited by 6
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)
Abdelmoteleb, S., Totlani, J., Ramadan, S., Salem, M., Meyer, A., Chang, T., Ewing, M., dos Santos, L. F. D. A. B., Murphy, N., Renteria, S., et al. (2025) · Neuroscience Applied · doi:10.1016/j.nsa.2025.105507 · Cited by 4
Brexpiprazole: A New Treatment Option for Schizophrenia.
Scarff, J. R. (2016) · PubMed Central · Cited by 4
Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
Correll, C. U., Mafi, C. E., Fagiolini, A. M., Seerden, P., Seifritz, E., Tiihonen, J., Vita, A., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s539306 · Cited by 4
Self-citation
Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis
Olgiati, P., Messina, A., Oliva, V., Luca, M., Luca, A., Baune, B. T., Ferri, R., & Serretti, A. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000607 · Cited by 3
Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI® Tablets 1 mg, 2 mg)
Suzuki, M., Niidome, K., Maeda, K., Kikuchi, T., Usami, T., & Futamura, T. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.275 · Cited by 3
New drug: Brexpiprazole for schizophrenia
(2017) · Australian Prescriber · doi:10.18773/austprescr.2017.064 · Cited by 3
Features of Clinical Use of Brexpiprazole, the New Atypical Antipsychotic of the Third Generation: Experience and Perspectives
Oleichik, I. V., Shishkovskaya, T. I., Баранов, П. А., & Nikiforova, I. Y. (2022) · Psikhiatriya · doi:10.30629/2618-6667-2022-20-3-134-142 · Cited by 3
Dopamine D2Partial Agonists – Discovery, Evolution, and Therapeutic Potential
Jacobson, M. A., Childers, W. E., & Abou-Gharbia, M. A. (2019) · Wiley eBooks · doi:10.1002/9783527814695.ch4 · Cited by 3
Aripiprazole versus brexpiprazole for people with schizophrenia
Martínez-Vélez, N. A., Escamilla-Orozco, R. I., Flores-Medina, Y., Saracco-Álvarez, R. A., Rosel-Vales, M., Salas, I. A., & Hernández, G. Y. S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014670 · Cited by 2
The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
Kikuchi, T., Maeda, K., Yamada, S., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_424-1 · Cited by 1
Combinación de antidepresivos vs. aumentación con antipsicóticos atípicos tras no lograr la remisión en la depresión unipolar
Philippi, R., & Correa, R. (2022) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272022000300337 · Cited by 1
Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis
Bano, S., Ahmad, A., Mohammed, A. H., Nurbekovna, I. R., Saad, S., Fatima, N., Akbar, M. B., Salahuddin, Z., Nabi, S., Ababneh, M. M., et al. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70332 · Cited by 1
Antipsychotic Drugs
Chue, P. S., & Siraki, A. G. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.029 · Cited by 1
The Dopamine D2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
Kikuchi, T., Maeda, K., Yamada, S., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_424 · Cited by 1
Effectiveness of brexpiprazole in the treatment in a patient with Huntington's disease
Mimura, Y., Funayama, M., Oi, H., Takata, T., Takeuchi, H., & Mimura, M. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12982 · Cited by 1
Indirect Meta-Analysis of Brexpiprazole Versus Aripiprazole in the Acute Treatment of SchizophreniaPreprint
Seifritz, E., Friede, M., & Schnitker, J. (2021) · Research Square · doi:10.21203/rs.3.rs-667245/v1
Brexpiprazole
Kopeček, M. (2019) · Praktické lékárenství · doi:10.36290/lek.2019.023
Treatment-Resistant Depression: Pharmacological Approach
Díaz, A. P., Quevedo, J., Sanches, M., & Soares, J. C. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.020
ANTIPSYCHOTIC DRUGS: THREE GENERATIONS OF ANTIPSYCHOTICS
Sukiasyan, S. G. (2024) · ARMENIAN JOURNAL OF MENTAL HEALTH · doi:10.55436/10.54436/1829202x-15.2024.1-3
Chapter 30. Aripiprazole and Brexpiprazole
Birze, N., Yuan, C., & Garcia-Pittman, E. C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as30
Self-Assessment of Impulsivity in Patients with Paranoid Schizophrenia in Exacerbation and Remission
Ma, M., Nikonova, E. Y., Rupchev, G., Lepilkina, T. A., Belyaev, S. A., Герович, Б. А., Burminskiy, D. S., Потанин, С. С., & Кибитов, А. А. (2024) · Psikhiatriya · doi:10.30629/2618-6667-2024-22-4-85-92
Clinical experience with the third-generation antipsychotic brexpiprazole in the treatment of schizophrenia spectrum disorders in a psychiatric inpatient settings
Chumakov, E. M., Bugorskij, A. V., & Васильевич, Л. О. (2025) · Medical alphabet · doi:10.33667/2078-5631-2024-33-51-57
Improving effects of additional administration of brexpiprazole to antipsychotics on cognitive function in patients with schizophrenia - A pilot study
Shimizu, Y., Takeuchi, I., Hanya, M., Fujita, K., & Kamei, H. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e44179
Aripiprazole versus Brexpiprazole for People with Schizophrenia: A Systematic Review
Flores-Medina, Y., Rosel-Vales, M., Escamilla-Orozco, R. I., Saracco-Álvarez, R. A., Guerrero-Medrano, A. F., Celada-Borja, C., Tiburcio, M., & Martínez-Vélez, N. A. (2025) · Salud Mental · doi:10.17711/sm.0185-3325.2025.035
Suicide Risk of Third-Generation Antipsychotics in Persons with Schizophrenia and Schizoaffective Disorders: A Systematic Review and Meta-AnalysisPreprint
Jin, J. W., Winkler, C. J., Blunt, H. B., & Riblet, N. B. V. (2026) · medRxiv · doi:10.64898/2026.02.10.26345876
Development of a Long-Acting Brexpiprazole Laurate Microcrystalline Suspension via Progressive Particle size Control for Schizophrenia Therapy
Li, Q., Liu, J., Wang, J., Fu, Q., Liu, J., Bian, W., Lu, W., & He, J. F. (2026) · Pharmaceutical Fronts · doi:10.1055/a-2799-4224
Exploring Combination Therapy for the Management of Psychotic Disorders: A Comprehensive Review
Sharma, S., Behl, D. S., Suri, P., Sharma, T., Rai, G., Gauba, P., & Dang, S. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128440388260522052532
Akathisia Associated with the Use of Third-Generation Antipsychotics: Clinical Data Analysis and Management Strategies
Андреевна, Б. В., Захаров, Д. В., & Mikhailov, V. A. (2026) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2026-2-1096
Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis
Jin, J. W., Winkler, C. J., Blunt, H. B., & Riblet, N. B. V. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.09.006

Authors: Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A.
Affiliations: New York Medical College (US)
Creative Commons (US)
Corresponding author: Citrome, Leslie
ORCID: Citrome, Leslie
Perry, Pamela
Baker, Ross A.
Venue: International Clinical Psychopharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2016-07
Volume: 31
Issue: 4
Pages: 192-201
ISSN: 0268-1315 (ISSN-L)
DOI: 10.1097/yic.0000000000000123
OpenAlex: W2295051011
Cited by: 74
References: 41
Citations by year: 2026: 6 · 2025: 9 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 8 · 2018: 2 · 2017: 7 · 2016: 6
FWCI: 6.82
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
Locations: International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: brexpiprazole, aripiprazole, acute schizophrenia, schizophrenia relapse, akathisia, impulsivity, cognitive function, antipsychotic efficacy, drug safety, hospitalization
MeSH terms: Aripiprazole, Acute Disease, Adult, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Schizophrenia, Thiophenes, Antipsychotic Agents, Quinolones, Weight Gain, Treatment Outcome, Akathisia, Drug-Induced, Serotonin Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks